HIV and hepatitis C virus coinfection in Canada: Challenges and opportunities for reducing preventable morbidity and mortality

HIV Medicine

Volumn 14, Issue 1, 2013, Pages 10-20

  Klein, M B ^a   Rollet, K C ^a   Saeed, S ^a   Cox, J ^b,c   Potter, M ^a   Cohen, J ^d   Conway, B ^e,p   Cooper, C ^f,q   Cote P ^g,r   Gill, J ^h   Haase, D ⁱ   Haider, S ^j   Harris, Marrianne ^t   Hull, M ^e,x   Moodie, E ^b   Montaner, J ^e,t   Pick, N ^e,u   Rachlis, A ^k,v   Rouleau, D ^l   Wong, David ^o   Sandre, R ^m,w   Tyndall, M ^f,n,s   Walmsley, S ^o,y   more..

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d WINDSOR REGIONAL HOSPITAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g Clinique Medicale du Quartier Latin   (Canada)

^h Southern Alberta HIV Clinic   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j MCMASTER UNIVERSITY   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^m SUDBURY REGIONAL HOSPITAL   (Canada)

ⁿ Native Health Clinic   (Canada)

^o UNIVERSITY HEALTH NETWORK   (Canada)

^p Downtown IDC   (Canada)

^q UNIVERSITY OF OTTAWA   (Canada)

^r Clinique du Quartier Latin   (Canada)

^s Native Health Centre   (Canada)

^t ST PAUL S HOSPITAL   (Canada)

^u Oak Tree Clinic   (Canada)

^v SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^w HAVEN Program   (Canada)

^x BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^y TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

Aboriginal health; Epidemiology; Hepatology; Infectious diseases; Public health

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANADA; END STAGE LIVER DISEASE; ETHNICITY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; POVERTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

ADULT; CANADA; CAUSE OF DEATH; COINFECTION; COST OF ILLNESS; FEMALE; HEALTH STATUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84870561430     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01028.x     Document Type: Article

References (40)

1. Hogg RS, Yip B, Kully C etal. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160: 659-665.
2. Lima VD, Hogg RS, Harrigan PR etal. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685-692.
3. Krajden M, Kuo M, Zagorski B etal. Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol 2010; 24: 717-726.
4. Basseri B, Yamini D, Chee G etal. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int 2010; 30: 1012-1018.
5. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl 1): 74-81.
6. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada Community Acquired Infections Division, Centre for Communicable Disease and Infection Control (Public Health Agency of Canada). 2007.
7. Graham CS, Baden LR, Yu E etal. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-569.
8. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112-1115.
9. Klein MB, Saeed S, Yang H etal. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol 2010; 39: 1162-1169.
10. Mathews WC, May S. EuroQol (EQ-5D) measure of quality of life predicts mortality, emergency department utilization, and hospital discharge rates in HIV-infected adults under care. Health Qual Life Outcomes 2007; 5: 1-9. Available at www.hqlo.com/content/5/1/5.
11. Bacchetti P, Tien PC, Seaberg EC etal. Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis 2007; 7: 1-11. Available at www.biomedcentral.com/1471-2334/7/145.
12. From the Centers for Disease Control and prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: 729-730.
13. Al-Mohri H, Cooper C, Murphy T etal. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6: 375-378.
14. Al-Mohri H, Murphy T, Lu Y etal. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44: 463-469.
15. Lo Re V 3rd, Lim JK, Goetz MB etal. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011; 20: 689-699.
16. Department of Demography, Université de Montréal. Canadian Human Mortality Database. Available at www.bdlc.umontreal.ca/chmd (accessed 19 September 2011).
17. Bayoumi A, Degani N, Remis R etal. HIV Infection. In: Bierman A, ed. Project for An Ontario Women's Health Evidence-Based Report (Volume 2). Toronto, ON: St. Mchael's Hospital and the Institute for Clinical Evaluative Sciences, 2011; 2-126.
18. Public Health Agency of Canada. HIV/AIDS Among Aboriginal People in Canada. HIV/AIDS Epi Updates, July 2010. Ottawa, ON, Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, 2010.
19. Wood E, Montaner JS, Yip B etal. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003; 169: 656-661.
20. Glass TR, De Geest S, Weber R etal. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006; 41: 385-392.
21. Gill VS, Lima VD, Zhang W etal. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50: 98-105.
22. Buchacz K, Baker RK, Palella FJ Jr etal. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24: 1549-1559.
23. Tedaldi E, Peters L, Neuhaus J etal. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008; 47: 1468-1475.
24. Thorpe J, Saeed S, Moodie EE etal. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV- hepatitis C virus co-infection. AIDS 2011; 25: 967-975.
25. Freeman AJ, Dore GJ, Law MG etal. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
26. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M etal. Clinical progression of hepatitis C virus - Related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active Antiretroviral therapy. Hepatology 2007; 46: 622-630.
27. Posthouwer D, Makris M, Yee TT etal. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109: 3667-3671.
28. Berenguer J, Alvarez-Pellicer J, Martin PM etal. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413.
29. Vellozzi C, Buchacz K, Baker R etal. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. J Viral Hepat 2011; 18: 316-324.
30. Grebely J, Raffa JD, Lai C etal. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-358.
31. Fleming CA, Craven DE, Thornton D etal. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97-100.
32. Schaefer M, Schmidt F, Folwaczny C etal. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-451.
33. Tjepkema M, Wilkins R, Senecal S etal. Mortality of Metis and registered Indian adults in Canada: an 11-year follow-up study. Health Rep 2009; 20: 31-51.
34. Zwahlen M, Harris R, May M etal. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38: 1624-1633.
35. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep 1998; 113 (Suppl 1): 75-80.
36. MacNeil J, Pauly B. Needle exchange as a safe haven in an unsafe world. Drug Alcohol Rev 2011; 30: 26-32.
37. Marshall BD, Milloy MJ, Wood E etal. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011; 377: 1429-1437.
38. Wood E, Tyndall MW, Montaner JS etal. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ 2006; 175: 1399-1404.
39. Weber R, Ledergerber B, Opravil M etal. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ 1990; 301: 1362-1365.
40. Bell J, Zador D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000; 22: 179-190.